1 / 5

Better Cancer Therapeutics through Better Biological Modeling

In collaboration with: Steve St. Jeor Mariana Bego Lisa Keyes The University of Nevada at Reno. Better Cancer Therapeutics through Better Biological Modeling. Danna Hargett Princeton University. Cancer Therapeutics.

gerd
Download Presentation

Better Cancer Therapeutics through Better Biological Modeling

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. In collaboration with: Steve St. Jeor Mariana Bego Lisa Keyes The University of Nevada at Reno Better Cancer Therapeutics through Better Biological Modeling • Danna Hargett • Princeton University

  2. Cancer Therapeutics Cytomegalovirus (CMV) infection has devastating effects on cancer patient survival CMV causes pneumonia 50% of the time in bone marrow transplant patients 75% mortality rate in the untreated 31% mortality rate with anti-viral treatment We need more effective CMV anti-virals

  3. Immune Evasion Reactivation Dormant Infection Cancer Treatment Drugs against LUNA Cancer Therapeutics Cytomegalovirus (CMV) infection has devastating effects on cancer patient survival

  4. Plan of Action Re-purify LUNA to identify LUNA binding molecules 1. 2. Add purified LUNA OrgCAST Compound Mixture Compounds which block block reactivation are potential drugs 3. Add binding molecules to infected monocytes 4. Stimulate viral Reactivation

  5. Challenges • Luna is only conserved in human and chimpanzee CMV preventing small animal model testing, such as mouse • Identified drug targets may be toxic Commercialization • Identified compounds can be licensed to pharmaceutical company for clinical evaluation • Monocyte Suspension System can be adapted to other infectious agents to form core technology for further therapeutics identification

More Related